Free Trial

Blueprint Medicines (BPMC) Competitors

Blueprint Medicines logo
$110.05 +6.10 (+5.87%)
Closing price 04:00 PM Eastern
Extended Trading
$112.25 +2.20 (+2.00%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BPMC vs. TEVA, BGNE, GMAB, VTRS, ITCI, SMMT, MRNA, RDY, CTLT, and SRPT

Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Genmab A/S (GMAB), Viatris (VTRS), Intra-Cellular Therapies (ITCI), Summit Therapeutics (SMMT), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry.

Blueprint Medicines vs.

Teva Pharmaceutical Industries (NYSE:TEVA) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, community ranking, earnings, risk, institutional ownership, dividends and valuation.

Teva Pharmaceutical Industries has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.

Teva Pharmaceutical Industries has a net margin of -5.73% compared to Blueprint Medicines' net margin of -29.48%. Teva Pharmaceutical Industries' return on equity of 42.92% beat Blueprint Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-5.73% 42.92% 7.25%
Blueprint Medicines -29.48%-112.30%-26.87%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries received 788 more outperform votes than Blueprint Medicines when rated by MarketBeat users. However, 68.27% of users gave Blueprint Medicines an outperform vote while only 67.82% of users gave Teva Pharmaceutical Industries an outperform vote.

CompanyUnderperformOutperform
Teva Pharmaceutical IndustriesOutperform Votes
1328
67.82%
Underperform Votes
630
32.18%
Blueprint MedicinesOutperform Votes
540
68.27%
Underperform Votes
251
31.73%

Blueprint Medicines has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Blueprint Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$15.85B1.57-$559M-$0.85-25.84
Blueprint Medicines$249.38M28.04-$506.98M-$2.11-52.16

In the previous week, Blueprint Medicines had 12 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 26 mentions for Blueprint Medicines and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.64 beat Blueprint Medicines' score of 0.59 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
7 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Blueprint Medicines
10 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries currently has a consensus price target of $22.13, indicating a potential upside of 0.72%. Blueprint Medicines has a consensus price target of $122.72, indicating a potential upside of 11.51%. Given Blueprint Medicines' higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.75
Blueprint Medicines
1 Sell rating(s)
6 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.65

Summary

Teva Pharmaceutical Industries beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks.

Get Blueprint Medicines News Delivered to You Automatically

Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BPMC vs. The Competition

MetricBlueprint MedicinesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$6.99B$6.19B$5.20B$9.14B
Dividend YieldN/A2.94%5.13%4.04%
P/E Ratio-52.169.7689.3117.33
Price / Sales28.04306.691,265.82136.54
Price / CashN/A61.4443.7535.97
Price / Book51.196.055.324.80
Net Income-$506.98M$154.62M$122.60M$224.91M
7 Day Performance25.87%-1.67%0.61%1.77%
1 Month Performance14.07%-2.34%1.50%2.22%
1 Year Performance38.64%0.93%27.22%20.66%

Blueprint Medicines Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BPMC
Blueprint Medicines
1.6497 of 5 stars
$110.05
+5.9%
$122.72
+11.5%
+29.1%$6.99B$249.38M-52.16640Analyst Forecast
Insider Trade
Short Interest ↑
Analyst Revision
Gap Up
TEVA
Teva Pharmaceutical Industries
1.2152 of 5 stars
$20.22
-3.4%
$20.88
+3.2%
+97.0%$22.91B$16.77B-23.7937,851Analyst Forecast
BGNE
BeiGene
2.3904 of 5 stars
N/A$253.69
+∞
N/A$18.03B$3.32B-22.4210,600Positive News
GMAB
Genmab A/S
4.4691 of 5 stars
$21.72
-1.9%
$45.20
+108.1%
-29.2%$14.37B$19.84B21.092,204Short Interest ↓
News Coverage
VTRS
Viatris
2.3449 of 5 stars
$11.75
+0.7%
$13.67
+16.3%
-3.5%$14.02B$15.05B-15.8837,000Short Interest ↑
ITCI
Intra-Cellular Therapies
3.7933 of 5 stars
$127.26
+34.1%
$97.23
-23.6%
+87.1%$13.49B$612.78M-146.27560Analyst Forecast
High Trading Volume
SMMT
Summit Therapeutics
2.8045 of 5 stars
$18.09
+1.3%
$33.57
+85.6%
+425.7%$13.34B$700,000.00-64.60105
MRNA
Moderna
4.7326 of 5 stars
$34.09
-19.3%
$78.83
+131.3%
-67.0%$13.12B$5.06B-5.865,600Analyst Forecast
Options Volume
Analyst Revision
News Coverage
Gap Down
High Trading Volume
RDY
Dr. Reddy's Laboratories
2.0099 of 5 stars
$15.29
-0.8%
$17.00
+11.2%
+7.4%$12.76B$3.35B24.4327,048News Coverage
CTLT
Catalent
1.2495 of 5 stars
$63.48
flat
$63.40
-0.1%
N/A$11.52B$4.42B-28.0916,900News Coverage
SRPT
Sarepta Therapeutics
4.9263 of 5 stars
$117.01
-6.2%
$178.71
+52.7%
+1.4%$11.18B$1.64B93.611,314Analyst Forecast
Analyst Revision
News Coverage

Related Companies and Tools


This page (NASDAQ:BPMC) was last updated on 1/17/2025 by MarketBeat.com Staff
From Our Partners